ArticleChemical science2024
Polarization of macrophages to an anti-cancer phenotype through
Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Harnessing macrophage signaling pathways and scalable engineering for next-generation immunotherapies.Signal transduction and targeted therapy · 2026Review
- Gardiquimod Nanoemulsion Targets Cutaneous Leishmaniasis Lesions Reducing Systemic Toxicity and Parasite Burden.Advanced healthcare materials · 2026Article
- Aptamer-guided upconversion nanoconstructs enable proximity-dependent and precise photodynamic therapy for MRSA-infected wounds.Materials today. Bio · 2026Article
- Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy.Nanomaterials (Basel, Switzerland) · 2026Review
- Tumor-associated macrophages in cancer: from mechanisms to application.Molecular biomedicine · 2025Review
- Emerging versatile nanozymes for the therapeutic and diagnostic applications of diseases.Journal of translational medicine · 2025Review
- Cu single-atom embedded g-CNature communications · 2025Article
- Supramolecular Materials and Strategies for Bioorthogonal Chemical Transformations.Chemical reviews · 2025Review
- Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment.Materials today. Bio · 2025Review
- Gold nanoparticles modulate macrophage polarization to promote skeletal muscle regeneration.Materials today. Bio · 2025Review
- Performance of Imidazoquinoline Glycoconjugate BAIT628 as a TLR7 Agonist Prodrug for Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Nanoparticle-Driven Skeletal Muscle Repair and Regeneration Through Macrophage-Muscle Stem Cell Interaction.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Functional hydrogels promote chronic infectious wound healing by re-rousing macrophage M1 and inducing bacterial copper-like death.Materials today. Bio · 2025Review
- Nanozyme-Based Strategies in Cancer Immunotherapy: Overcoming Resistance to Enhance Therapeutic Efficacy.Aging and disease · 2025Review
- Research advancements in nanoparticles and cell-based drug delivery systems for the targeted killing of cancer cells.Oncology research · 2025Review
- Targeting of TAMs: can we be more clever than cancer cells?Cellular & molecular immunology · 2024Review
- All-Natural Gelatin-Based Nanoemulsion Loaded with TLR 7/8 Agonist for Efficient Modulation of Macrophage Polarization for Immunotherapy.Nanomaterials (Basel, Switzerland) · 2024Article
- Sarcoidosis and Cancer: The Role of the Granulomatous Reaction as a Double-Edged Sword.Journal of clinical medicine · 2024Article
- Nanosensor-Enabled Detection and Identification of Intracellular Bacterial Infections in Macrophages.Biosensors · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Macrophages are plastic cells of the immune system that can be broadly classified as having pro-inflammatory (M1-like) or anti-inflammatory (M2-like) phenotypes. M2-like macrophages are often associated with cancers and can promote cancer growth and create an immune-suppressive tumor microenvironment. Repolarizing macrophages from M2-like to M1-like phenotype provides a crucial strategy for anticancer immunotherapy. Imiquimod is an FDA-approved small molecule that can polarize macrophages by activating toll-like receptor 7/8 (TLR 7/8) located inside lysosomes. However, the non-specific inflammation that results from the drug has limited its systemic application. To overcome this issue, we report the use of gold nanoparticle-based bioorthogonal nanozymes for the conversion of an inactive, imiquimod-based prodrug to an active compound for macrophage re-education from anti- to pro-inflammatory phenotypes. The nanozymes were delivered to macrophages through endocytosis, where they uncaged pro-imiquimod
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.